Rosacea
Conditions
Interventions
placebo group:Oral placebo 0.3g + original treatment plan
high dose group:Oral gabapentin 0.3g tid
low dose group:Oral gabapentin 0.2g tid + placebo 0.1g
Sponsors
Xiangya Hospital of Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Definition of refractory rosacea: After 12 weeks (or more) of oral conventional drugs such as doxycycline, with or without other treatments (such as topical drugs/IPL, etc.), treatment resistance (the erythema has not decreased by 1 Patients with grade or erythema greater than or equal to 3 or flushing and other symptoms affecting quality of life (DLQI moderate and above), or patients with frequent recurrence during the 12-week treatment period; 2. Voluntarily sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Age65; 2. Pregnant and lactating women and those who have a recent pregnancy plan; 3. Patients with systemic diseases such as diabetes, moderate and severe liver, kidney, lung or blood; 4. Patients with depression or mental disorder; 5. Chronic pancreatitis; 6. Facial manifestations of rosacea patients with hypertrophic nose or other facial skin diseases (such as seborrheic dermatitis, eczema, etc.) or other diseases (such as dermatomyositis, systemic lupus erythematosus); 7. Engaged in driving or high-altitude operation or complex mechanical operation; 8. Patients who are not expected to insist on follow-up; 9. Those who have participated in any clinical trial within one month; 10. Allergies to gabapentin or any other component of the drug; 11. Other conditions that the researcher thinks cannot be included in the group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rosacea Clinical Symptom Severity Assessment (Patient Assessment);Rosacea Clinical Symptom Severity Assessment (Physician Assessment); | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life scale for patients with rosacea (self-assessment by patients);Anxiety and Depression Rating Scale (patient self-assessment);Facial clinical photos of rosacea patients;Anxiety and Depression Rating Scale (patient self-assessment);Facial VISIA photos of rosacea patients;Safety indicators (physical examination, vital signs, routine blood and urine, liver and kidney function, adverse events); | — |
Countries
China
Contacts
Public ContactLi Ji
Department of Dermatology, Xiangya Hospital, Central South University
Outcome results
None listed